Journal of Clinical Immunology

, Volume 33, Issue 7, pp 1156–1164

The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901

  • Christopher C. Dvorak
  • Morton J. Cowan
  • Brent R. Logan
  • Luigi D. Notarangelo
  • Linda M. Griffith
  • Jennifer M. Puck
  • Donald B. Kohn
  • William T. Shearer
  • Richard J. O’Reilly
  • Thomas A. Fleisher
  • Sung-Yun Pai
  • I. Celine Hanson
  • Michael A. Pulsipher
  • Ramsay Fuleihan
  • Alexandra Filipovich
  • Frederick Goldman
  • Neena Kapoor
  • Trudy Small
  • Angela Smith
  • Ka-Wah Chan
  • Geoff Cuvelier
  • Jennifer Heimall
  • Alan Knutsen
  • Brett Loechelt
  • Theodore Moore
  • Rebecca H. Buckley
Original Research

DOI: 10.1007/s10875-013-9917-y

Cite this article as:
Dvorak, C.C., Cowan, M.J., Logan, B.R. et al. J Clin Immunol (2013) 33: 1156. doi:10.1007/s10875-013-9917-y

Abstract

The Primary Immune Deficiency Treatment Consortium (PIDTC) consists of 33 centers in North America. We hypothesized that the analysis of uniform data on patients with severe combined immunodeficiency (SCID) enrolled in a prospective protocol will identify variables that contribute to optimal outcomes following treatment. We report baseline clinical, immunologic, and genetic features of the first 50 patients enrolled, and the initial therapies administered, reflecting current practice in the diagnosis and treatment of both typical (n = 37) and atypical forms (n = 13) of SCID. From August 2010 to May 2012, patients with suspected SCID underwent evaluation and therapy per local center practices. Diagnostic information was reviewed by the PIDTC eligibility review panel, and hematopoietic cell transplantation (HCT) details were obtained from the Center for International Blood and Marrow Transplant Research. Most patients (92 %) had mutations in a known SCID gene. Half of the patients were diagnosed by newborn screening or family history, were younger than those diagnosed by clinical signs (median 15 vs. 181 days; P = <0.0001), and went to HCT at a median of 67 days vs. 214 days of life (P = <0.0001). Most patients (92 %) were treated with HCT within 1–2 months of diagnosis. Three patients were treated with gene therapy and 1 with enzyme replacement. The PIDTC plans to enroll over 250 such patients and analyze short and long-term outcomes for factors beneficial or deleterious to survival, clinical outcome, and T- and B-cell reconstitution, and which biomarkers are predictive of these outcomes.

Keywords

Severe combined immunodeficiencyhematopoietic cell transplantationnewborn screening

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Christopher C. Dvorak
    • 1
  • Morton J. Cowan
    • 1
  • Brent R. Logan
    • 2
  • Luigi D. Notarangelo
    • 3
  • Linda M. Griffith
    • 4
  • Jennifer M. Puck
    • 1
  • Donald B. Kohn
    • 5
  • William T. Shearer
    • 6
  • Richard J. O’Reilly
    • 7
  • Thomas A. Fleisher
    • 8
  • Sung-Yun Pai
    • 9
  • I. Celine Hanson
    • 6
  • Michael A. Pulsipher
    • 10
  • Ramsay Fuleihan
    • 11
  • Alexandra Filipovich
    • 12
  • Frederick Goldman
    • 13
  • Neena Kapoor
    • 14
  • Trudy Small
    • 7
  • Angela Smith
    • 15
  • Ka-Wah Chan
    • 16
  • Geoff Cuvelier
    • 17
  • Jennifer Heimall
    • 18
  • Alan Knutsen
    • 19
  • Brett Loechelt
    • 20
  • Theodore Moore
    • 21
  • Rebecca H. Buckley
    • 22
  1. 1.Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, Benioff Children’s HospitalUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Division of Biostatistics, Center for International Blood and Marrow Transplant ResearchMedical College of WisconsinMilwaukeeUSA
  3. 3.Division of Immunology and The Manton Center for Orphan Disease Research, Children’s Hospital BostonHarvard Medical SchoolBostonUSA
  4. 4.Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA
  5. 5.Departments of Microbiology, Immunology & Molecular Genetics and Pediatrics, University of California Los AngelesLos AngelesUSA
  6. 6.Departments of Pediatrics and Pathology & ImmunologyBaylor College of MedicineHoustonUSA
  7. 7.Department of PediatricsMemorial Sloan Kettering Cancer CenterNew YorkUSA
  8. 8.Department of Laboratory MedicineNational Institutes of HealthBethesdaUSA
  9. 9.Division of Hematology and Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer InstituteBostonUSA
  10. 10.Division of Hematology and Hematologic Malignancies, Primary Children’s Medical CenterUniversity of Utah School of Medicine/Huntsman Cancer InstituteSalt Lake CityUSA
  11. 11.Division of Allergy and Immunology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of MedicineChicagoUSA
  12. 12.Division of Hematology/OncologCincinnati Children’s HospitalCincinnatiUSA
  13. 13.Division of Hematology and Oncology, The Children’s Hospital of AlabamaUniversity of AlabamaTuscaloosaUSA
  14. 14.Division of Research Immunology and Bone Marrow TransplantationChildren’s Hospital of Los AngelesLos AngelesUSA
  15. 15.Division of Pediatric Blood and Marrow TransplantationUniversity of MinnesotaMinneapolisUSA
  16. 16.Pediatric Stem Cell Transplantation ProgramTexas Transplant InstituteSan AntonioUSA
  17. 17.Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, Department of Pediatrics and Child HealthUniversity of ManitobaWinnipegCanada
  18. 18.Division of Allergy/ImmunologyThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  19. 19.Division of Pediatric Allergy & ImmunologySt. Louis UniversitySt LouisUSA
  20. 20.Blood and Marrow Transplantation, Allergy and ImmunologyChildren’s National Medical CenterWashingtonUSA
  21. 21.Division of Pediatric Hematology/OncologyUniversity of California Los AngelesLos AngelesUSA
  22. 22.Departments of Pediatrics & ImmunologyDuke University Medical CenterDurhamUSA